Diamantis Xylas is the Head of Research at Catalio Capital Management, LP. He is primarily responsible for managing Catalio’s research team and makes investments in breakthrough biomedical technology companies founded by world renowned scientist-entrepreneurs. He also serves on the Nexus Investment Committee and the firmwide Management Committee.
Diamantis currently serves on the Boards of Spiral Therapeutics, Haystack Oncology and Octant Bio, as well as Catalio Capital UK, Ltd., the firm’s UK subsidiary.
Prior to joining Catalio, Diamantis completed two years of General Surgery residency at Johns Hopkins Hospital, as well as two years of postgraduate medical and surgical training in London, UK. He has also worked as a visiting research fellow at Weil Cornell Medical Center in New York, where he investigated the role of genes in the development of bladder cancer.
Diamantis earned his MBBS (Bachelor of Medicine, Bachelor of Surgery) degree at Imperial College School of Medicine in London, and his BSc. degree in Healthcare Management from Imperial College Business School.